我們已在上線！進一步了解

NeuroOne Medical Technologies

NMTC

市值 US$875萬

0.9614 USD

-0.0786

7.56%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

1.00

+0.04

4.01%

1天

-7.56%

5天

-12.6%

1個月

-31.82%

3個月

-59.43%

6個月

-78.96%

今年迄今

-81.19%

1年

-81.44%

5年

-94.57%

10年

-97.79%

關於： NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.

員工： 18

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 100%

負面 0%

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027 EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology.

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

EDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, today announced a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System.

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

Zacks Investment Research

Best Momentum Stocks to Buy for January 6th

RIGL, CM and NMTC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6th, 2026.

Best Momentum Stocks to Buy for January 6th

Zacks Investment Research

New Strong Buy Stocks for January 6th

ILPT, NMTC, RIGL, RIO and BHP have been added to the Zacks Rank #1 (Strong Buy) List on January 6th, 2026.

New Strong Buy Stocks for January 6th

NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript

查看新聞排名

價格圖表採用Lightweight Charts™實作